Abstract
Methylenedioxypyrovalerone (MDPV) is the most popular synthetic cathinone found in products marketed as ‘bath salts’, widely abused among teenagers and young adults. Synthetic cathinones have pharmacological effects resembling those of psychostimulants, which are known to disrupt a variety of social behaviors. However, despite the popular use of MDPV by young people in social contexts, information about its effects on social behavior is scarce. To investigate the impact of MDPV on social behavior at young age, and the underlying neurobehavioral mechanisms, we focused on social play behavior. Social play behavior is the most characteristic social behavior displayed by young mammals and it is crucial for neurobehavioral development. Treatment with MDPV reduced social play behavior in both juvenile and young adult male rats, and its play-suppressant effect was subject to tolerance but not sensitization. As the behavioral effects of MDPV have been ascribed to dopaminergic and noradrenergic neurotransmission, and given the role of these neurotransmitters in social play, we investigated the involvement of dopamine and noradrenaline in the play-suppressant effects of MDPV. The effects of MDPV on social play were blocked by either the α2 adrenoceptor antagonist RX821002 or the dopamine receptor antagonist flupenthixol, given alone or together at sub-effective doses. In sum, MDPV selectively suppresses the most vigorous social behavior of developing rats through both noradrenergic and dopaminergic mechanisms. This study provides important preclinical evidence of the deleterious effects of MDPV on social behavior, and as such increases our understanding of the neurobehavioral effects of this popular cathinone.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Karila L, Lafaye G, Scocard A, Cottencin O, Benyamina A. MDPV and alpha-PVP use in humans: the twisted sisters. Neuropharmacology. 2018;134:65–72.
Valente MJ, Guedes de Pinho P, de Lourdes Bastos M, Carvalho F, Carvalho M. Khat and synthetic cathinones: a review. Arch Toxicol. 2014;88:15–45.
Ashrafioun L, Bonadio FA, Baik KD, Bradbury SL, Carhart VL, Cross NA, et al. Patterns of use, acute subjective experiences, and motivations for using synthetic cathinones (“bath salts”) in recreational users. J Psychoact Drugs. 2016;48:336–43.
German CL, Fleckenstein AE, Hanson GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 2014;97:2–8.
Zawilska JB, Wojcieszak J. Designer cathinones-an emerging class of novel recreational drugs. Forensic Sci Int. 2013;231:42–53.
European Monitoring Centre for Drugs and Drug Addiction. EMCDDA–Europol Joint Report on a new psychoactive substance: MDPV (3,4-methylenedioxypyrovalerone), joint reports. Luxembourg: Publications Office of the European Union; 2014.
Angoa-Perez M, Anneken JH, Kuhn DM. Neurotoxicology of synthetic cathinone analogs. Curr Top Behav Neurosci. 2017;32:209–30.
Baumann MH, Partilla JS, Lehner KR. Psychoactive “bath salts”: not so soothing. Eur J Pharmacol. 2013;698:1–5.
Froberg BA, Levine M, Beuhler MC, Judge BS, Moore PW, Engebretsen KM, et al. Acute methylenedioxypyrovalerone toxicity. J Med Toxicol. 2015;11:185–94.
Weaver MF, Hopper JA, Gunderson EW. Designer drugs 2015: assessment and management. Addict Sci Clin Pract. 2015;10:8.
Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology. 2013;71:130–40.
Atehortua-Martinez LA, Masniere C, Campolongo P, Chasseigneaux S, Callebert J, Zwergel C, et al. Acute and chronic neurobehavioral effects of the designer drug and bath salt constituent 3,4-methylenedioxypyrovalerone in the rat. J Psychopharmacol. 2019;33:392–405.
Glennon RA, Young R. Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) and alpha-pyrrolidinovalerophenone (alpha-PVP). Brain Res Bull. 2016;126:111–26.
Achterberg EJ, Trezza V, Siviy SM, Schrama L, Schoffelmeer AN, Vanderschuren LJ. Amphetamine and cocaine suppress social play behavior in rats through distinct mechanisms. Psychopharmacology. 2014;231:1503–15.
Miczek KA, Haney M, Tidey J, Vatne T, Weerts E, DeBold JF. Temporal and sequential patterns of agonistic behavior: effects of alcohol, anxiolytics and psychomotor stimulants. Psychopharmacology.1989;97:149–51.
Moro M, Salvador A, Simòn VM. Changes in the structure of the agonistic behavior of mice produced by d-amphetamine. Pharmacol Biochem Behav. 1997;56:47–54.
Schiorring E. Social isolation and other behavioral changes in groups of adult vervet monkeys (Cercopithecus aethiops) produced by low, nonchronic doses of d-amphetamine. Psychopharmacology. 1979;64:297–302.
Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168:458–70.
De-Giorgio F, Bilel S, Ossato A, Tirri M, Arfe R, Foti F, et al. Acute and repeated administration of MDPV increases aggressive behavior in mice: forensic implications. Int J Leg Med. 2019;133:1797–808.
Bateson P. Playfulness and creativity. Curr Biol. 2015;25:R12–6.
Nijhof SL, Vinkers CH, van Geelen SM, Duijff SN, Achterberg EJM, van der Net J, et al. Healthy play, better coping: the importance of play for the development of children in health and disease. Neurosci Biobehav Rev. 2018;95:421–9.
Pellis SM, Pellis VC. The playful brain. Oxford: Oneworld Publications; 2009.
Spinka M, Newberry RC, Bekoff M. Mammalian play: training for the unexpected. Q Rev Biol. 2001;76:141–68.
Manduca A, Campolongo P, Palmery M, Vanderschuren LJ, Cuomo V, Trezza V. Social play behavior, ultrasonic vocalizations and their modulation by morphine and amphetamine in Wistar and Sprague-Dawley rats. Psychopharmacology. 2014;231:1661–73.
Helgeland MI, Torgersen S. Stability and prediction of schizophrenia from adolescence to adulthood. Eur Child Adolesc Psychiatry. 2005;14:83–94.
Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344:1398–402.
Jordan R. Social play and autistic spectrum disorders: a perspective on theory, implications and educational approaches. Autism: Int J Res Pract. 2003;7:347–60.
Moller P, Husby R. The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior. Schizophr Bull. 2000;26:217–32.
Alessandri SM. Attention, play, and social behavior in ADHD preschoolers. J Abnorm Child Psychol. 1992;20:289–302.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1577–9.
Kilkenny C, Parsons N, Kadyszewski E, Festing MFW, Cuthill IC, Fry D, et al. Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals. PLoS ONE. 2009;4:e7824.
Pellis SM, McKenna M. What do rats find rewarding in play fighting? An analysis using drug-induced non-playful partners. Behav Brain Res. 1995;68:65–73.
Pellis SM, McKenna MM. Intrinsic and extrinsic influences on play fighting in rats: effects of dominance, partner’s playfulness, temperament and neonatal exposure to testosterone propionate. Behav Brain Res. 1992;50:135–45.
Trezza V, Vanderschuren LJ. Cannabinoid and opioid modulation of social play behavior in adolescent rats: differential behavioral mechanisms. Eur Neuropsychopharmacol. 2008;18:519–30.
Varlinskaya EI, Spear LP, Spear NE. Social behavior and social motivation in adolescent rats: role of housing conditions and partner's activity. Physiol Behav. 1999;67:475–82.
Trezza V, Baarendse PJ, Vanderschuren LJ. The pleasures of play: pharmacological insights into social reward mechanisms. Trends Pharmacol Sci. 2010;31:463–9.
Vanderschuren LJ, Achterberg EJ, Trezza V. The neurobiology of social play and its rewarding value in rats. Neurosci Biobehav Rev. 2016;70:86–105.
Achterberg EJ, van Kerkhof LW, Damsteegt R, Trezza V, Vanderschuren LJ. Methylphenidate and atomoxetine inhibit social play behavior through prefrontal and subcortical limbic mechanisms in rats. J Neurosci. 2015;35:161–9.
Achterberg EJ, van Kerkhof LW, Servadio M, van Swieten MM, Houwing DJ, Aalderink M, et al. Contrasting roles of dopamine and noradrenaline in the motivational properties of social play behavior in rats. Neuropsychopharmacol. 2016;41:858–68.
Vanderschuren LJ, Trezza V, Griffioen-Roose S, Schiepers OJ, Van Leeuwen N, De Vries TJ, et al. Methylphenidate disrupts social play behavior in adolescent rats. Neuropsychopharmacol. 2008;33:2946–56.
Manduca A, Lassalle O, Sepers M, Campolongo P, Cuomo V, Marsicano G, et al. Interacting cannabinoid and opioid receptors in the nucleus accumbens core control adolescent social play. Front Behav Neurosci. 2016;10:211.
Niesink RJ, Van Ree JM. Involvement of opioid and dopaminergic systems in isolation-induced pinning and social grooming of young rats. Neuropharmacology.1989;28:411–8.
Pellis SM, Pellis VC. Play-fighting differs from serious fighting in both target of attack and tactics of fighting in the laboratory rat rattus norvegicus. Aggress Behav. 1987;13:227–42.
Manduca A, Morena M, Campolongo P, Servadio M, Palmery M, Trabace L, et al. Distinct roles of the endocannabinoids anandamide and 2-arachidonoylglycerol in social behavior and emotionality at different developmental ages in rats. Eur Neuropsychopharmacol. 2015;25:1362–74.
Bara A, Manduca A, Bernabeu A, Borsoi M, Serviado M, Lassalle O, et al. Sex-dependent effects of in utero cannabinoid exposure on cortical function. Elife. 2018;7:e36234.
Cameron KN, Kolanos R, Solis E Jr., Glennon RA, De Felice LJ. Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol. 2013;168:1750–7.
Bernstein DL, Nayak SU, Oliver CF, Rawls SM, Rom S. Methylenedioxypyrovalerone (MDPV) impairs working memory and alters patterns of dopamine signaling in mesocorticolimbic substrates. Neurosci Res. 2019;155:56–62.
Baumann MH, Bukhari MO, Lehner KR, Anizan S, Rice KC, Concheiro M, et al. Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its metabolites, and related analogs. Curr Top Behav Neurosci. 2017;32:93–117.
Panksepp J, Siviy S, Normansell L. The psychobiology of play: theoretical and methodological perspectives. Neurosci Biobehav Rev. 1984;8:465–92.
Andrabi S, Greene S, Moukaddam N, Li B. New drugs of abuse and withdrawal syndromes. Emerg Med Clin North Am. 2015;33:779–95.
Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30:194–202.
Fernandez M, Mollinedo-Gajate I, Penagarikano O. Neural circuits for social cognition: implications for autism. Neuroscience. 2018;370:148–62.
Berridge KC. The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology. 2007;191:391–431.
Hambuchen MD, Hendrickson HP, Gunnell MG, McClenahan SJ, Ewing LE, Gibson DM, et al. The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats. Drug Alcohol Depend. 2017;179:347–54.
McClenahan SJ, Hambuchen MD, Simecka CM, Gunnell MG, Berquist MD, Owens SM. Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats. Drug Alcohol Depend. 2019;195:140–7.
King HE, Wakeford A, Taylor W, Wetzell B, Rice KC, Riley AL. Sex differences in 3,4-methylenedioxypyrovalerone (MDPV)-induced taste avoidance and place preferences. Pharmacol Biochem Behav. 2015;137:16–22.
Author information
Authors and Affiliations
Contributions
SS, FM, EC, and PJP performed the experiments. SS, AMan, and EC analysed and contributed to the design of the behavioral experiments. EC VB, and AMan contributed to data analysis. CZ, AMai, PC, and LJMJV contributed to the design of the experiments and edited the paper. SS wrote the paper. VT supervised the project, designed the experiments and wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Schiavi, S., Melancia, F., Carbone, E. et al. Detrimental effects of the ‘bath salt’ methylenedioxypyrovalerone on social play behavior in male rats. Neuropsychopharmacol. 45, 2012–2019 (2020). https://doi.org/10.1038/s41386-020-0729-5
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41386-020-0729-5
